Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ALFACELL WILL FILE IND FOR ANTICANCER BIOLOGICAL PANNON,

  • News

Executive Summary

ALFACELL WILL FILE IND FOR ANTICANCER BIOLOGICAL PANNON, the company announced Aug. 12, after meeting with FDA's Center for Drugs and Biologics in a prefiling conference to discuss details of the proposed study. The filing will reportedly take place in eight to ten weeks, and the company is planning to conduct a multi-center trial in the U.S. The release noted that Alfacell's pre-filing conference with FDA was based on a clinical study conducted in the Domenican Republic, in which 27 terminal cancer patients were treated with Pannon. According to Dr. Angel S. Chan Aquino, former Domenican Minister of Health and director of the clinical trial, all patients "showed significant malignant cell destruction." It has also been reported that the drug did not produce any significant side effects.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS008786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By